91福利 research partner joins global incubator network JLABS, Toronto
YYZ鈥檚 President and COO Mike Badeau (left) and 91福利鈥檚 Faculty of Science professor John Marshall.
A key commercialization partner and spin-out of a 91福利 (91福利) biochemistry lab has been accepted as a resident company of Johnson & Johnson's global incubator network, JLABS, Toronto.
YYZ Pharmatech Inc. (YYZ) is a deep tech company endeavouring to profoundly progress new medicine for patients by revealing the plasma proteome. This residency grants access to JLABS鈥� global network of innovation ecosystems. JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad health-care spectrum, including pharmaceutical and medical technology sectors.
鈥�91福利 has been an important long-term partner to YYZ, and we are thrilled to celebrate this milestone together,鈥� said Mike Badeau, President and COO of YYZ.
Professor John G. Marshall, head of 91福利鈥檚 Research Analytical Biochemistry Lab (RABL), has collaborated with YYZ for over 20 years, pioneering plasma proteomics research 鈥� the study of proteins in blood plasma.
Harnessing plasma proteins for disease diagnosis and treatment
Their advances enable early disease diagnosis, predicting disease risk and identifying new therapeutic targets. Plasma proteins serve as biomarkers and potential drug targets for many diseases, including cardiovascular disease, cancer and neurodegenerative conditions. They also play key roles in immune response, blood clotting and transporting hormones and nutrients.
鈥淎s key regulators of human health, plasma ligands and their cell surface receptors are crucial targets of therapeutic treatments and current medical research,鈥� said professor Marshall. 鈥淪ince 2004, our research at 91福利 has focused on developing advanced tools that integrate biochemistry, mass spectrometry and computational analysis with laboratory techniques to drive new discoveries in this field.鈥�
鈥淐ongratulations to professor Marshall and YYZ Pharmatech for this exciting opportunity to join JLABS and a global innovation ecosystem,鈥� said Steven N. Liss, vice-president, research and innovation at 91福利. 鈥淭his is an important step to accelerate the trajectory of this exciting and promising work to deliver impactful, novel health-care innovations.鈥�
Research by The Marshall Team at 91福利 is supported by the Natural Sciences and Engineering Research Council of Canada.
Learn more about The Marshall Team鈥檚 Research Analytical Biochemistry Lab (RABL) at 91福利.
Related link: